摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6a,6b-dimethyl-hexahydro-3a,5,8,9a-tetraaza-cyclohepta[def]biphenylene-4,6,7,9-tetraone | 25878-29-9

中文名称
——
中文别名
——
英文名称
6a,6b-dimethyl-hexahydro-3a,5,8,9a-tetraaza-cyclohepta[def]biphenylene-4,6,7,9-tetraone
英文别名
3,15-Dimethyl-5,7,11,13-tetrazatetracyclo[9.4.0.02,7.03,15]pentadecane-4,6,12,14-tetrone
6a,6b-dimethyl-hexahydro-3a,5,8,9a-tetraaza-cyclohepta[<i>def</i>]biphenylene-4,6,7,9-tetraone化学式
CAS
25878-29-9
化学式
C13H16N4O4
mdl
——
分子量
292.294
InChiKey
RIQXVIINDMCVKR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -1.3
  • 重原子数:
    21
  • 可旋转键数:
    0
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.69
  • 拓扑面积:
    98.8
  • 氢给体数:
    2
  • 氢受体数:
    4

反应信息

  • 作为产物:
    描述:
    1,1'-(1,3-丙烷二基)二胸腺嘧啶丙酮 作用下, 以 为溶剂, 反应 7.5h, 以54%的产率得到6a,6b-dimethyl-hexahydro-3a,5,8,9a-tetraaza-cyclohepta[def]biphenylene-4,6,7,9-tetraone
    参考文献:
    名称:
    三重态能量转移与激发态环化反应是光敏联嘧啶二聚化的控制步骤。
    摘要:
    聚亚甲基连接的联嘧啶模型已设计为具有不同的C5取代基和桥长度。用联嘧啶模型选择性辐照2'-甲氧基苯乙酮(2M),即使存在庞大的取代基也能得到环丁烷嘧啶二聚体。C5处的取代影响嘧啶(Pyr)的相对三重态能量(ET(rel))以及分子间能量转移和分子内三重态Pyr *猝灭的空间位阻。光物理研究表明,烷基取代导致ET(rel)值显着降低。证明了Pyr衍生物对2M的三重激发态的猝灭,并建立了它们的猝灭速率常数(kq)。作为一般趋势,含胸腺嘧啶的化合物的kq值高于109 M-1 s-1,而在尿嘧啶和叔丁基尿嘧啶类似物中,kq显着降低。这些数据是在三种不同的情况下进行解释的:(a)三重态能量转移是速率控制步骤,(b)激发态环化是速率控制步骤,并且(c)速率控制步骤随反应而变化。因此,通过在C5处的取代,连接桥的长度或底物浓度上引入变化,可以从由固有二聚化步骤控制的过程切换至能量转移控制的过程。
    DOI:
    10.1021/acs.joc.9b01423
点击查看最新优质反应信息

文献信息

  • Transient UV–vis absorption spectroscopic characterisation of 2′-methoxyacetophenone as a DNA photosensitiser
    作者:Ofelia R. Alzueta、M. Consuelo Cuquerella、Miguel A. Miranda
    DOI:10.1016/j.saa.2019.04.007
    日期:2019.7
    absorption as compared with other acetophenone derivatives. On the basis of transient infrared spectroscopy it has been previously claimed that 2M is an interesting photosensitiser for cyclobutane pyrimidine dimers (CPDs) formation. In the present paper, a complete UV–Vis transient absorption spectroscopic characterisation of this compound is provided, including triplet-triplet spectra, triplet lifetimes
    2'-甲氧基苯乙酮(2M)与其他苯乙酮衍生物相比,具有更高的UVA吸收率。在瞬态红外光谱的基础上,先前已声称2M是用于形成环丁烷嘧啶二聚体(CPD)的有趣的光敏剂。在本文中,提供了该化合物的完整的UV-Vis瞬态吸收光谱表征,包括三重态-三重态光谱,三重态寿命和通过二聚胸腺嘧啶衍生物淬灭2M的速率常数。此外,通过时间分辨的近红外磷光测量已证明了单线态氧的产生。总体而言,获得的结果证实了2M的潜力 作为一种DNA光敏剂,不仅用于CPD的形成,而且还用于氧化损伤。
  • DNA−Protein Cross-Linking:  Model Systems for Pyrimidine−Aromatic Amino Acid Cross-Linking
    作者:Guangxing Sun、Christopher J. Fecko、Robert B. Nicewonger、Watt W. Webb、Tadhg P. Begley
    DOI:10.1021/ol052876m
    日期:2006.2.1
    We have synthesized simple model systems to explore the possibility of photo-cross-linking between the pyrimidine bases and the side chains of the aromatic amino acids. Thymine/phenylalanine and thymine/tyrosine models gave cross-links, and thymine/tryptophan models gave complex mixtures; the cytosine/phenylalanine model was unreactive. The quantum yields for the model cross-linking reactions were 18-46 times smaller than those for thymine dimer formation. Biphotonic excitation contributes little to the yield of these reactions.
  • Triplet Energy Transfer versus Excited State Cyclization as the Controlling Step in Photosensitized Bipyrimidine Dimerization
    作者:Ofelia R. Alzueta、M. Consuelo Cuquerella、Miguel A. Miranda
    DOI:10.1021/acs.joc.9b01423
    日期:2019.11.1
    triplet energy transfer is the rate controlling step, (b) excited state cyclization is the rate controlling step, and (c) the rate controlling step switches along the reaction. Thus, by introducing variations in the substitution at C5, the length of the linking bridge, or the substrate concentration, it is possible to switch from a process governed by the intrinsic dimerization step to an energy transfer-controlled
    聚亚甲基连接的联嘧啶模型已设计为具有不同的C5取代基和桥长度。用联嘧啶模型选择性辐照2'-甲氧基苯乙酮(2M),即使存在庞大的取代基也能得到环丁烷嘧啶二聚体。C5处的取代影响嘧啶(Pyr)的相对三重态能量(ET(rel))以及分子间能量转移和分子内三重态Pyr *猝灭的空间位阻。光物理研究表明,烷基取代导致ET(rel)值显着降低。证明了Pyr衍生物对2M的三重激发态的猝灭,并建立了它们的猝灭速率常数(kq)。作为一般趋势,含胸腺嘧啶的化合物的kq值高于109 M-1 s-1,而在尿嘧啶和叔丁基尿嘧啶类似物中,kq显着降低。这些数据是在三种不同的情况下进行解释的:(a)三重态能量转移是速率控制步骤,(b)激发态环化是速率控制步骤,并且(c)速率控制步骤随反应而变化。因此,通过在C5处的取代,连接桥的长度或底物浓度上引入变化,可以从由固有二聚化步骤控制的过程切换至能量转移控制的过程。
查看更多

同类化合物

阿斯普尼辛B 阿斯普尼辛 D 阿斯普尼辛 苯佐莫文 新骏河毒素 乙酰胺,N-(4-硝基-2-吡啶基)-,氧化(9CI) TAK960抑制剂 PLK1抑制剂(RO3280) 8H-嘧啶并[4,5-b][1,4]二氮杂卓 8-甲基-5,9-二氢-6H-嘧啶并[4,5-b][1,4]重氮基庚英-6-酮 6H-嘧啶并[4,5-b][1,4]二氮杂卓 4-甲基-6,11-二氢-3H-嘧啶并[4,5-b][1,5]苯并二氮杂卓-2,5-二酮 2-氯-7,7-二氟-5-甲基-5,7,8,9-四氢-6H-嘧啶基[4,5-B][1,4]二氮杂-6-酮 2-氯-5-甲基-5,7,8,9-四氢-6H-嘧啶[4,5-B][1,4]二氮杂6-酮 1H-嘧啶并[4,5-b][1,4]二氮杂卓 4-amino-8-(1,3-benzodioxol-5-yl)-6-phenyl-8,9-dihydro-7H-pyrimido[4,5-b][1,4]diazepine 2-(2-Bromo-4-isopropyl-phenyl)-4-methyl-6-pentyl-6,7,8,9-tetrahydro-2H-2,3,5,6,9a-pentaaza-benzo[cd]azulen-1-one 2-chloro-8-(trifluoromethyl)-6H,11H-benzo[b]pyrimidino[5,4-f]-1,4-diazaperhydroepin-5-one 4,5,6,7-tetrahydro-2,4-diphenyl-4,7a,12b-triazadibenzo[e,g]azulene-1,3,8-trione 4,5,6,7-tetrahydro-4-methyl-2-phenyl-4,7a,12b-triazadibenzo[e,g]azulene-1,3,8-trione N-(4-((8,9-dimethoxy-5-methyl-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-11H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-5-methyl-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-6-oxo-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-fluorophenyl)-N-(4-((8-methoxy-2-methyl-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)phenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-6-oxo-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-fluorophenyl)-N-(4-((8-methoxy-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)phenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-11H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide di-tert-butyl (1r,4r)-4-(4-(9-cyclohexyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-3-methoxybenzamido)cyclohexyl phosphate 2-(2-Bromo-4-isopropyl-phenyl)-6-(1-ethyl-propyl)-4-methyl-6,7,8,9-tetrahydro-2H-2,3,5,6,9a-pentaaza-benzo[cd]azulen-1-one 7,8,9,10-tetrahydro-10-hydroxy-9-heptyl-[1,4]diazepino[1,2,3-g,h]purine 7,8,9,10-tetrahydro-10-hydroxy-9-methyl-9-propyl[1,4]diazepino[1,2,3-g,h]purine 6-cyclopentyl-9-[(3-methoxyphenyl)amino]-2-methyl-2,6,8,10-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-3-one 6-cyclopentyl-9-[(2-methoxyphenyl)amino]-2-methyl-2,6,8,10-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-3-one tert-butyl 8,10-dibromo-7-oxo-1,2,5,5a,6,7-hexahydro-[1,4]diazepino[1,7-a]quinazoline-3(4H)-carboxylate tert-butyl 8,10-dimethyl-7-oxo-1,2,5,5a,6,7-hexahydro-[1,4]diazepino[1,7-a]quinazoline-3(4H)-carboxylate 11-Diallylaminoacetyl-6-isopropyl-5,6-dihydropyrimido[4,5-b][1,5]benzodiazepin-5-one 6-butyl-11-diallylaminoacetyl-2-phenyl-5,6-dihydropyrimido[4,5-b][1,5]benzodiazepin-5-one 11-chloroacetyl-6-isopropyl-5,6-dihydropyrimido[4,5-b][1,5]benzodiazepin-5-one 4-[(2-cyclopentyl-4,4,6-trimethyl-5-oxo-2,6,9,11-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-10-yl)amino]benzoic acid 4-[(2-cyclopentyl-6-methyl-5-oxo-2,6,9,11-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-10-yl)amino]-3-methoxy-N-(4-piperidyl)benzamide 4-[(6-cyclopentyl-2-methyl-3-oxo-2,6,8,10-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-9-yl)amino]-N-(1-ethyl-4-piperidyl)-3-methoxy-benzamide 8-(4-chlorophenyl)-6-phenyl-9H-pyrimido[4,5-b][1,4]diazepin-4-ol 1-chloro-7-methoxy-8-(3-morpholin-4-yl-propoxy)-10,11-dihydro-5H-2,4,5,11-tetraaza-dibenzo[a,d]cycloheptene 4-[(6-cyclopentyl-2-methyl-3-oxo-2,6,8,10-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-9-yl)amino]-3-methoxy-N-methyl-benzamide (S)-tert-butyl (4-chloro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-7-yl)carbamate 3-methoxy-4-[[6-(2-methoxyethyl)-2-methyl-3-oxo-2,6,8,10-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-9-yl]amino]-N-(1-methyl-4-piperidyl)benzamide (9aS,9R)-4-chloro-N-(4-methylphenyl)-9a,10,11,12-tetrahydro-9H-pyrimido[4,5-b]dipyrrolo[1,2-d:2',1'-g][1,4]diazepin-9-amine